IL33614A - Mastitis immuno-globulin,its preparation and use for treating mastitis in cows - Google Patents
Mastitis immuno-globulin,its preparation and use for treating mastitis in cowsInfo
- Publication number
- IL33614A IL33614A IL33614A IL3361469A IL33614A IL 33614 A IL33614 A IL 33614A IL 33614 A IL33614 A IL 33614A IL 3361469 A IL3361469 A IL 3361469A IL 33614 A IL33614 A IL 33614A
- Authority
- IL
- Israel
- Prior art keywords
- mastitis
- globulin
- immuno
- process according
- penicillin
- Prior art date
Links
- 208000004396 mastitis Diseases 0.000 title claims description 126
- 108060003951 Immunoglobulin Proteins 0.000 title claims description 96
- 102000018358 immunoglobulin Human genes 0.000 title claims description 96
- 241000283690 Bos taurus Species 0.000 title claims description 60
- 238000002360 preparation method Methods 0.000 title description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 48
- 210000002966 serum Anatomy 0.000 claims description 31
- 210000004369 blood Anatomy 0.000 claims description 29
- 239000008280 blood Substances 0.000 claims description 29
- 230000008569 process Effects 0.000 claims description 27
- 229940056360 penicillin g Drugs 0.000 claims description 23
- 239000003242 anti bacterial agent Substances 0.000 claims description 18
- 230000003115 biocidal effect Effects 0.000 claims description 18
- 210000000481 breast Anatomy 0.000 claims description 12
- 230000000521 hyperimmunizing effect Effects 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 239000004599 antimicrobial Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 238000010790 dilution Methods 0.000 claims description 8
- 239000012895 dilution Substances 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- 230000002335 preservative effect Effects 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 6
- 229930182555 Penicillin Natural products 0.000 claims description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 6
- 239000001166 ammonium sulphate Substances 0.000 claims description 6
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 5
- ASXBYYWOLISCLQ-UHFFFAOYSA-N Dihydrostreptomycin Natural products O1C(CO)C(O)C(O)C(NC)C1OC1C(CO)(O)C(C)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O ASXBYYWOLISCLQ-UHFFFAOYSA-N 0.000 claims description 5
- 102000006395 Globulins Human genes 0.000 claims description 5
- 108010044091 Globulins Proteins 0.000 claims description 5
- 239000000910 agglutinin Substances 0.000 claims description 5
- 229960002222 dihydrostreptomycin Drugs 0.000 claims description 5
- ASXBYYWOLISCLQ-HZYVHMACSA-N dihydrostreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O ASXBYYWOLISCLQ-HZYVHMACSA-N 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 229940049954 penicillin Drugs 0.000 claims description 5
- CZWJCQXZZJHHRH-YCRXJPFRSA-N 2-[(1r,2r,3s,4r,5r,6s)-3-(diaminomethylideneamino)-4-[(2r,3r,4r,5s)-3-[(2s,3s,4s,5r,6s)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O CZWJCQXZZJHHRH-YCRXJPFRSA-N 0.000 claims description 4
- 239000003146 anticoagulant agent Substances 0.000 claims description 4
- 229940127219 anticoagulant drug Drugs 0.000 claims description 4
- 230000009036 growth inhibition Effects 0.000 claims description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 4
- 108010001478 Bacitracin Proteins 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229930193140 Neomycin Natural products 0.000 claims description 3
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 claims description 3
- 229960003071 bacitracin Drugs 0.000 claims description 3
- 229930184125 bacitracin Natural products 0.000 claims description 3
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims description 3
- 210000000601 blood cell Anatomy 0.000 claims description 3
- 229960005091 chloramphenicol Drugs 0.000 claims description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 229960003276 erythromycin Drugs 0.000 claims description 3
- 229960001625 furazolidone Drugs 0.000 claims description 3
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 229960004927 neomycin Drugs 0.000 claims description 3
- 229960002950 novobiocin Drugs 0.000 claims description 3
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 claims description 3
- 238000011176 pooling Methods 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims description 2
- 230000002949 hemolytic effect Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 229960005322 streptomycin Drugs 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 48
- 239000000047 product Substances 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 17
- 239000008267 milk Substances 0.000 description 14
- 235000013336 milk Nutrition 0.000 description 14
- 210000004080 milk Anatomy 0.000 description 14
- 229940088710 antibiotic agent Drugs 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 230000004520 agglutination Effects 0.000 description 9
- 230000036039 immunity Effects 0.000 description 9
- 206010016654 Fibrosis Diseases 0.000 description 8
- 230000004761 fibrosis Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 108010074605 gamma-Globulins Proteins 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000003053 toxin Substances 0.000 description 7
- 231100000765 toxin Toxicity 0.000 description 7
- 108700012359 toxins Proteins 0.000 description 7
- 230000004523 agglutinating effect Effects 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002101 lytic effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229940126572 wide-spectrum antibiotic Drugs 0.000 description 3
- 101710186708 Agglutinin Proteins 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 101710146024 Horcolin Proteins 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 101710189395 Lectin Proteins 0.000 description 2
- 101710179758 Mannose-specific lectin Proteins 0.000 description 2
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 2
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 239000006161 blood agar Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 150000002605 large molecules Chemical class 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000031462 Bovine Mastitis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018913 Haemolyses Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 101710124951 Phospholipase C Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA69333 | 1969-01-17 | ||
| ZA691780 | 1969-03-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL33614A0 IL33614A0 (en) | 1970-02-19 |
| IL33614A true IL33614A (en) | 1973-08-29 |
Family
ID=27130988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL33614A IL33614A (en) | 1969-01-17 | 1969-12-26 | Mastitis immuno-globulin,its preparation and use for treating mastitis in cows |
Country Status (16)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL1019143C2 (nl) * | 2001-10-08 | 2003-04-09 | Nutricia Nv | Farmaceutisch product of voedingssupplement en daarbij te gebruiken tussenproduct. |
| RU2338375C2 (ru) * | 2006-09-04 | 2008-11-20 | Государственное образовательное учреждение высшего профессионального образования "Удмуртский государственный университет" | Способ хранения плазмы или сыворотки крови для получения иммуноглобулиновых и альбуминовых биопрепаратов |
-
1969
- 1969-12-26 IL IL33614A patent/IL33614A/en unknown
-
1970
- 1970-01-09 AT AT514671A patent/AT309134B/de not_active IP Right Cessation
- 1970-01-14 MT MT639A patent/MTP639B/xx unknown
- 1970-01-14 CH CH47670A patent/CH560543A5/de not_active IP Right Cessation
- 1970-01-15 NO NO70145A patent/NO130179B/no unknown
- 1970-01-15 DE DE2001671A patent/DE2001671C3/de not_active Expired
- 1970-01-16 ES ES375511A patent/ES375511A1/es not_active Expired
- 1970-01-16 DK DK19270AA patent/DK128981B/da unknown
- 1970-01-16 IE IE62/70A patent/IE33944B1/xx unknown
- 1970-01-16 CA CA072,282A patent/CA954045A/en not_active Expired
- 1970-01-16 FR FR7001552A patent/FR2034472B1/fr not_active Expired
- 1970-01-16 NL NL7000637.A patent/NL164746C/xx not_active IP Right Cessation
- 1970-01-16 BE BE744515D patent/BE744515A/xx not_active IP Right Cessation
- 1970-01-17 IT IT47859/70A patent/IT1044200B/it active
- 1970-01-17 OA OA53835A patent/OA03892A/xx unknown
- 1970-01-19 GB GB1297011D patent/GB1297011A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR2034472A1 (enrdf_load_stackoverflow) | 1970-12-11 |
| DK128981B (da) | 1974-08-05 |
| NL7000637A (enrdf_load_stackoverflow) | 1970-07-21 |
| AT309134B (de) | 1973-08-10 |
| DE2001671A1 (de) | 1970-07-30 |
| IT1044200B (it) | 1980-03-20 |
| FR2034472B1 (enrdf_load_stackoverflow) | 1974-03-22 |
| DE2001671B2 (de) | 1980-09-25 |
| NO130179B (enrdf_load_stackoverflow) | 1974-07-22 |
| BE744515A (fr) | 1970-07-01 |
| NL164746B (nl) | 1980-09-15 |
| OA03892A (fr) | 1975-08-14 |
| IE33944L (en) | 1970-07-17 |
| NL164746C (nl) | 1981-02-16 |
| DK128981C (enrdf_load_stackoverflow) | 1975-01-20 |
| DE2001671C3 (de) | 1981-10-08 |
| GB1297011A (enrdf_load_stackoverflow) | 1972-11-22 |
| MTP639B (en) | 1970-07-22 |
| IL33614A0 (en) | 1970-02-19 |
| IE33944B1 (en) | 1974-12-11 |
| ES375511A1 (es) | 1973-04-16 |
| CH560543A5 (enrdf_load_stackoverflow) | 1975-04-15 |
| CA954045A (en) | 1974-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3917818A (en) | Treatment of mastitis in cows, the product for this treatment and to the production of said product | |
| US3984539A (en) | Bovine immunoglobulin isolation process | |
| GB1573995A (en) | Process for the production of a protein concentrate containing immunological factors of lactic origin | |
| US4027010A (en) | Antistaphylococcous human immunoglobulin and method of preparing same | |
| JPH0253408B2 (enrdf_load_stackoverflow) | ||
| EP0694309A2 (en) | Vaccine, antigens and antibodies containing compound for inhibiting and preventing induced staphylococcus infection | |
| JP2002501526A (ja) | 乳汁における免疫グロブリンａの生成方法 | |
| EP0484148A1 (en) | A method for producing a new medicine for both treating and preventing peptic ulcer diseases and gastritis and thus formulated medicines | |
| US20220267419A1 (en) | Human Immunoglobulin Against Methicillin-Resistant Staphylococcus Aureus, Preparation Method Therefor, And Use Thereof | |
| EP0527971B1 (en) | Composition and method for immunostimulation in mammals | |
| DK158334B (da) | Fremgangsmaade til fremstilling af polypeptidfraktioner fra muslinger | |
| DE69731891T2 (de) | Verfahren zur reinigung von gbs-toxin/cm101 | |
| Avery | The distribution of the immune bodies occurring in antipneumococcus serum | |
| JPH08504167A (ja) | スタフィロコーカス感染の予防及び処理のための指図されたヒト免疫グロブリン | |
| IL33614A (en) | Mastitis immuno-globulin,its preparation and use for treating mastitis in cows | |
| US3992521A (en) | Immunological product for the treatment of intestinal infections due to pathogenic enterobacteria of the infant | |
| HowARD et al. | The use of antilymphoblast globulin in the treatment of renal allograft rejection: a double-blind, randomized study | |
| RU2062109C1 (ru) | Способ получения иммунного препарата | |
| US5198215A (en) | Composition for controlling mastitis in ruminants, method for its preparation and method of treatment of ruminants | |
| US11197893B2 (en) | Pure platelet-rich plasma (P-PRP) composition for treatment of subclinical mastitis and methods of producing and using the same | |
| CN102731652A (zh) | 纳米脂质体抗牛乳房炎耐药致病菌特异性复合IgY的制备方法及其制剂 | |
| RU2470664C2 (ru) | Способ получения иммуноглобулина для внутривенного введения, обогащенного иммуноглобулином м, и препарат, полученный этим способом | |
| Ziv et al. | Binding of antibiotics to dry udder secretion and to udder tissue homogenates | |
| DE69719049T2 (de) | Pharmazeutische zusammensetzung, enthaltend komplementproteine, zur behandlung von helicobacter-infektionensowie ein verfahren zur herstellung der zusammensetzung | |
| AT300193B (de) | Verfahren zur Herstellung von Mastitis-Immunoglobulin |